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Background: Human cancer cells resemble stem cells in expression signatures leading them to share some
features, most notably, self-renewal. A complex network of transcription factors and signaling molecules are
required for continuance of this trait. SALL4 is a zinc finger transcriptional activator crucial for maintenance of
self-renewal in stem cells; however, its expression level has not yet been elucidated in colorectal tumor cells. To
determine this level and probable clinicopathological consequences, its expression was analyzed.
Methods: SALL4 expression in fresh tumoral and distant tumor-free tissues from 46 colorectal samples was
compared by real-time polymerase chain reaction (PCR).
Results: Greater than a two-fold increase in SALL4 expression was detected in 87% of tumors vs. normal related
tissues. SALL4 expression was significantly correlated with tumor cell metastasis to lymph nodes, especially in
moderately-differentiated tumor samples (P < 0.05). Furthermore, higher levels of SALL4 mRNA expression were
significantly associated with younger than older patients with tumor cells in stages I and II (P < 0.05).
Conclusions: These results indicate a relationship between SALL4 expression and tumor cell metastasis to lymph
nodes and consequent advancement of tumors to advanced stages III and IV. Along with the promising evidence
of its role in self-renewal in various cancers, SALL4 may have a role in progression, development and maintenance
of colorectal cancers.
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Colorectal cancer (CRC) is the third most common can-
cer in men and the second in women worldwide [1]. Al-
most 60% of the cases occur in developed regions where
the age standardized rate for incidence (ASR) is 37.6/105
in males and 24.2/105 in females. Causing approximately
8% of all cancer deaths, CRC is the fourth most common
cause of cancer-related death globally. The ASR for mor-
tality in developed regions is 15.1/105 and 9.7/105 in
males and females, respectively [1]. This cancer develops
in a multistep progression; from normal colonic epithe-
lium to an ultimately invasive cancer, as a result of
pathologic transformation including molecular events in
a variety of pathways [2]. Therefore, identification of* Correspondence: Forghanifard@damghaniau.ac.ir
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distribution, and reproduction in any mediumcritical factors that may be involved in initiation and
progress of this multistep carcinogenic pathway may
provide insights into effective therapies to combat CRC.
The SALL gene family, including four members
(SALL1 to SALL4) was initially cloned based on DNA
sequence homology to Drosophila gene spalt (sal) [3].
Sal is an essential homeotic gene for the development of
the fly [4]. The human SALL gene family is involved in
normal development. Structural properties of human
SALL consist of several C2H2 zinc finger domains that
can bind DNA, and in some cases, RNA and proteins
[5]. In embryonic stem cells (ESCs), SALL4 has signifi-
cant roles in the maintenance of pluripotency and self-
renewal, efficient proliferation/stabilization, and cell fate
decision [6,7]. It is also engaged in maintenance of
human adult stem cell features [8]. Depending on ESCs
context, the transcription factor SALL4 activates or
represses various engrossed transcriptional networksentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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crucial transcription factors and epigenetic modulators.
SALL4 is also engaged in the regulation of chromatin re-
modeling by bridging transcriptional regulation and epi-
genetic regulation in stem cells [9]. Having direct
interaction with key cell-signaling pathways such as Wnt
and TGF-beta, SALL4 can play essential roles in cell fate
decision and survival of ESCs [10,11]. SALL4 is an im-
portant regulator of the stemness state and survival, not
only in several types of normal stem cells, but also in
cancer cells and possibly cancer stem cells [12].
In adults, SALL4 expression is normally restricted to
CD34+ hematopoietic stem/progenitor cells [10], and in
adult mice, SALL4 is also predominantly expressed in
testes and ovaries [13]. Nonetheless, SALL4 expression
is reported in numerous malignancies, such as breast
and lung cancers [14,15], precursor B-cell lymphoblastic
lymphoma [16], myelodysplastic syndromes (MDS) [11],
acute myeloid leukemia (AML) [10,11], endometriotic
samples [17], ovarian germ cell tumors [18], all types of
testicular germ cell tumors (GCTs) [19], all metastatic
seminomas/dysgerminomas and embryonal carcinomas
[20], and primary mediastinal yolk sac tumors (YSTs)
[21]. It is suggested that SALL4 not only might be im-
portant in pathogenesis of GCTs, especially to maintain
their poorly differentiated status, but also can be used as
a highly specific marker to confirm the germ cell origin
of a metastatic tumor, due to its sensitivity and specifi-
city [19,20]. Furthermore, it is proposed that SALL4 may
have diagnostic and therapeutic value in breast and lung
cancers [14,15].
An intricate network of genetic and epigenetic aberra-
tions involving various signaling pathways is responsible
for the development of CRC. Unlike blood malignancies
and GSTs, few studies have focused on the molecular
epidemiology of SALL4 in other cancers and there are
no reports of SALL4 gene expression and its probable
role in CRC to date. Having considered its involvement
in tumorigenesis, progression, and aggressiveness of
various tumors, our aim in this study was to analyze




Fresh tumoral and distant tumor-free colorectal tissues
were obtained through colorectal surgery at Omid On-
cology Hospital of Mashhad University of Medical
Sciences (MUMS), Iran, from 46 patients who had not
received any other therapeutic intervention such as
chemo- or radiotherapy. After collection, the specimens
were immediately treated with RNAlater solution
(Qiagen, Hilden, Germany) and stored at −20°C until ex-
traction. The ethics committee of MUMS approved thestudy and all patients formally declared their consent to
be enrolled. Histopathological characteristics of tumor
samples such as tumor size, location, and differentiation
grading were recorded. Tumor-free colorectal tissues
were also confirmed histologically to ensure that all the
included samples are normal. Furthermore, based on the
Union International Cancer TNM classification guide-
lines, the surgical stages of the tumoral samples were
defined [22].
cDNA synthesis and quantitative real-time-PCR
RNA extractions and cDNA syntheses were performed
as described previously [23]. Quantitative real-time PCR
was carried out using SYBR green PCR Master Mix
(Fermentas, Lithuania), containing ROX as a reference
dye on a Stratagene Mx-3000P real-time thermocycler
(Stratagene, La Jolla, CA) with the primers presented in
Table 1. The thermal profile included 10 min at 95°C fol-
lowed by 40 cycles of 15 sec at 95°C, 30 sec at 57°C, and
45 sec at 72°C. Data were normalized to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression [24]
applying the comparative threshold cycle method. The
PCR efficiencies for GAPDH and SALL4 were verified
by generating related standard curves. The relative levels
of SALL4 gene expression were compared based on
fluorescence intensity changes of samples from tumor
vs. corresponding normal tissues. A more than two-fold
increase in expression was considered to be overexpres-
sion, while a more than two-fold decrease was consid-
ered to be underexpression. The range between those
two values was interpreted as no change or normal ex-
pression. All experiments were performed in triplicate.
Statistical analysis
Data was analyzed using the SPSS 19.9 statistical pack-
age (SPSS, Chicago, IL). Based on requirements, either
the χ2 or Fisher exacts test were applied to assess the
correlations between gene expression and various histo-
pathological features. Independent sample t test and
ANOVA were used also to correlate gene expression
levels and different categorical data. P values < 0.05 were
considered to be statistically significant.
Results
Fresh frozen colorectal tumors and corresponding
normal-margin specimens of 46 newly-diagnosed patients
were obtained through surgery prior to any other treat-
ments, ensuring that histopathological characteristics of
CRC tissues were not affected by therapeutic intervention.
Based on microscopy, all the tumoral samples contained
more than 75% tumor cells, with rare or no infiltrating
cells. This procedure helped to ensure precise evaluation
of gene expression in tumor cells compared to normal.
SALL4 expression was analyzed by reverse transcription
Table 1 Primer sequences used for quantitative real-time RT-PCR
Forward primer sequence Reverse primer sequence
SALL4 CCAAAGGCAACTTAAAGGTTCAC CCGTGAAGACCAATGAGATCTC
GAPDH GGAAGGTGAAGGTCGGAGTCA GTCATTGATGGCAACAATATCCACT
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ard deviation (SD) of the enrolled patients was 53.80 ±
14.89 (age range 21–86). The male-to-female ratio was
1.3:1 (26:20). The tumors were resected from distal and
proximal regions of the colon with a size range from 3 to
10 cm (mean ± SD: 4.85 ± 1.55). Clinicopathological fea-
tures of the patients are presented in Table 2.
Upregulation of SALL4 in CRC
We compared SALL4 mRNA expression in 46 tumor
specimens to their paired non-neoplastic colorectal epi-
thelium by quantitative real time-PCR. The expression
pattern of the gene in patients is represented as a scatter
plot in Figure 1. Significant overexpression of SALL4
mRNA was detected in 40 of 46 of tumor specimens
(87%, P < 0.0001). The minimum and maximum mRNATable 2 Clinicopathological features of the patients and




value↑ ↓ / -
Tumor invasion
T1, T2 8 (17.4%) 8 0 0.538
T3, T4 38 (82.6%) 32 6
Lymph node metastasis
N0 33 (71.7%) 28 5 0.047*
N1 9 (19.6%) 9 0
N2 4 (8.7) 3 1
Stage
I/II 34 (73.9%) 29 5 0.397
III/IV 12 (26.1%) 11 1
Grade
WD 29 (63%) 25 4 0.020*
MD 16 (34.8%) 15 1
PD 1 (2.2%) 0 1
Tumor location
Proximal 13 (28.3%) 11 2 0.611
Distal 33 (71.7%) 29 4
Sex
Male 26 (56.5%) 22 4 0.030*
Female 20 (43.5%) 18 2
WD: Well differentiated; MD: Moderately differentiated;
PD: Poorly differentiated.
*Significant correlation between SALL4 mRNA expression and
clinicopathological feature.expression changes were −5.28- and 14.30-fold, respect-
ively (Mean ± SD, 5.33 ± 3.59). Since a few patients
showed normal or underexpression of the gene (six
patients) we merged them to a single group in compari-
son with SALL4 overexpressed patients. The related
means and standard deviations were 6.37±2.36 in
patients with SALL4 overexpression and -1.61 ± 2.42 in
other patients. Figure 2 schematically compares expres-
sion levels in both groups. Clinicopathological features
of the patients with normal or underexpression of
SALL4 mRNA are summarized in Table 3.
Association of SALL4 expression with clinicopathological
variables
To evaluate the clinicopathological consequences of
SALL4 expression in CRC, we analyzed the correlation
of various clinicopathological variables with SALL4
mRNA level (Table 2). We observed that SALL4 expres-
sion correlated with multiple indices of poor prognosis.
SALL4 expression was significantly associated with
tumor cell metastasis to lymph nodes (P < 0.05). Of nine
patients with lymph node metastasis, all (100%) overex-
pressed SALL4 (mean ± SD: 6.45 ± 1.38), while in 15.2%
of patients (5 of 33) without metastasis to lymph nodes
SALL4 was not overexpressed (mean ± SD: 4.68 ± 3.72).
Additionally, expression of SALL4 was associated with
the grade of tumor cell differentiation. Twenty-five of 29
(86.2%) well-differentiated and fifteen of 16 (93.8%)
moderately-differentiated tumors overexpressed SALL4
(P < 0.05). No significant associations were observed be-
tween SALL4 expression and other clinicopathological
variables such as tumor stages or tumor invasion depth.
For further analyses, we assessed the correlations be-
tween SALL4 gene expression and different clinico-
pathological features in samples that overexpressed
SALL4. SALL4 overexpression was significantly corre-
lated with sex (P = 0.030, correlation coefficient: 0.384).
SALL4 gene expression was significantly higher in males
than females (mean ± SD: 5.25 ± 3.60 and 3.96 ± 2.45,
respectively). Furthermore, in the same group, SALL4
expression was inversely correlated with patients’ ages (P
= 0.034, correlation coefficient: -0.395). Thus, SALL4 ex-
pression is lower in tumor cells of older patients than
younger ones.
In advanced tumor stages (stages III and IV), a signifi-
cant inverse correlation was observed between SALL4
overexpression and the number of involved lymph nodes
(P = 0.006, correlation coefficient: -0.737). In addition,
Figure 1 Scatter plot representative of descriptive analysis of
relative gene expression distribution of SALL4 in patients with
CRC. The Y axis indicates the relative gene expression, and the X
axis represents the patients. Relative mRNA expression of more than
two-fold in tumor tissues is considered as overexpression, less than
minus two-fold as underexpression, and the range in-between is
defined as normal.
Figure 2 Box plot representative of relative mRNA expression
of SALL4 in CRC patients. Quantitative analysis of SALL4 is
represented as box plots. The Y axis indicates the fold change of
relative mRNA expression, and the X axis represents patient groups.
Box plots represent the lowest, lower quartile, median, upper
quartile, and highest observations of fold changes in patients either
with normal/underexpressed or overexpressed SALL4.
Table 3 Clinicopathological features of six tumor samples
with normal or underexpression of SALL4 mRNA
Clinicopathological feature Description
Sex 4 female, 2 male
Age One patient is 21, others ranged 54-66
Location of tumor 2 proximal, 4 distal
Grade of tumor 4 WD, 1 MD, 1 PD
Stage of tumor 5 in stage II, 1 in stage III
Lymph node metastasis 5 without metastasis, 1 with metastasis
Depth of tumor invasion All are invaded to adventitia (T3)
Size of tumor Ranged 3–10 cm
WD: Well differentiated; MD: Moderately differentiated;
PD: Poorly differentiated.
Forghanifard et al. Journal of Biomedical Science 2013, 20:6 Page 4 of 7
http://www.jbiomedsci.com/content/20/1/6in tumor samples without invasion to adventitia (T1,
T2), SALL4 gene expression significantly correlated with
patients’ ages (P = 0.033, correlation coefficient: -0.967).
In such tumor samples, SALL4 expression was signifi-
cantly higher in younger than older patients.
Discussion
Expression analysis of SALL4 in normal and tumor colo-
rectal tissues elucidated overexpression of SALL4 in a
nearly 90% of CRC samples, where SALL4 expression
was significantly associated with tumor cell metastasis to
lymph nodes and the grade of tumor cell differentiation.
There are some similar studies reporting the overexpres-
sion of SALL4 in different malignancies. In breast can-
cer, it is demonstrated that 86.1% of tumor samples
showed elevated levels of SALL4 mRNA expression,
where the increased levels of SALL4 mRNA expression
were observed even in the early stages of tumors [14].
However, there was not any significant correlation be-
tween clinicopathological features of the patients and
SALL4 mRNA expression in breast cancer [14]. Further-
more, it has been shown that 93% of lung tumors
revealed SALL4 overexpression in mRNA levels [15].
These data may emphasize the role of SALL4 in carcino-
genesis of different cancers specially by considering the
results of related complementary studies.
Silencing of SALL4 in breast cancer cell line, MCF7,
inhibits its propagation [14]. Furthermore, having
silenced the SALL4 in SBC-1 lung cancer cells, Kobaya-
shi et al. demonstrated that SALL4 has a critical role in
the proliferation of lung cancer cells [15]. They showedthat decreasing of SALL4 mRNA level to the baseline by
43% resulted in tragedic growth inhibition by 93.5% [15].
Therefore, SALL4 can be detected with high sensitivity
and specificity and may have diagnostic and therapeutic
value in breast and lung cancers [14,15].
It has been shown that all types of testicular GCTs ex-
press SALL4 protein in correlation with degree of tumor
differentiation and suggested that SALL4 is essetial for the
maintanance of poorly differentiated status [19]. Also, ex-
pression of SALL4 was detected in more than 90% of
tumor cells of metastatic seminomas, dysgerminomas and
embryonal carcinomas suggesting that SALL4 play a role
in development of germ cell tumors [20]. Based on these
results, SALL4 is introduced as a novel sensitive and
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novel diagnostic marker for metastatic yolk sac tumors
from the testis, ovary, and extragonadal sites [20].
In this study, six samples showed normal or underex-
pression of SALL4 mRNA. As summarized in Table 3,
five of them had not metastasis to lymph nodes being in
stage II and all of six samples showed tumor invasion to
adventitia (T3), intrestingly. Since SALL4 mRNA expres-
sion is significantly correlated with metastasis of tumor
cell to lymph node in CRCs, it may be remarkable that
83.3% of samples without SALL4 overexpression (5 of 6)
have not showed metastasis to lymph node. These data
may confirm the significant role of SALL4 mRNA ex-
pression in progression and lymph node metastasis of
CRCs. We conclude from this results that increased ex-
pression of this stem cell transcription factor in CRC
may be contributed in CRC tumorigenesis. Nonetheless,
Analysis of different aspects of SALL4 in stem cell biol-
ogy along with existing related data on CRC may help us
to understand how SALL4 functions in CRC cells, and
which cellular processes involving SALL4 may be
involved in CRC pathogenesis.
SALL4, a member of the Spalt family, is a homeotic
gene originally identified in Drosophila as a transcription
factor required for development [25]. The transcriptional
network of SALL4/OCT4/Nanog is crucial for the main-
tenance of “stemness” of ES cells [12] whereas SALL4,
as a core factor, plays a dominant role in this regulatory
network [8]. It activates OCT4 as a transcriptional factor
and interacts with Nanog in a protein-protein complex
[26,27]. Due to the same genomic binding sites of
SALL4 and Nanog, reciprocal regulation of these pro-
teins is suggested in governing pluripotency and self-
renewal of ES cells [27]. Interestingly, overexpression of
OCT4 and Nanog has been shown in CRC samples. Ex-
pression of OCT4 was increased with CRC stage pro-
gression [28]. Furthermore, overexpression of Nanog
was significantly correlated with poor prognosis, lymph
node metastasis, and TNM classification of colorectal
cancer [29,30]. These data, along with SALL4 overex-
pression, which is reported here, lead us to hypothesize
the existence of activated similar regulatory transcrip-
tional networks in colorectal tumor cells playing essen-
tial roles in proliferation and self-renewal characteristics
of tumor cells. Considering the existence of the stemness
regulatory network of SALL4/OCT4/Nanog in CRC
cells, we suggest that the pathogenesis of CRC and evo-
lution of colorectal malignancy might be related to
abundance and contribution of stem cell-like cells in the
tumors. Our results support the hypothesis of cancer
stem cell-based tumor development and progression.
SALL4 increases levels of histones H3–K4 and H3–K79
trimethylations in the Bmi-1 promoter in association with
a methyltransferase in vivo [31]. Bmi-1 is a component ofa polycomb group (PcG) multiprotein complex required
to maintain the transcriptionally repressive state of many
genes, including Hox genes, throughout development
[32]. Our data shows SALL4 overexpression in significant
correlation with lymph node metastasis and epithelial-
mesenchymal transition (EMT). Furthermore, Bmi1 is
overexpressed in CRC samples associated with degree of
differentiation, status of lymph node metastasis, and TNM
staging in colorectal cancer [33]. Combining these data
and results, we propose that the role of SALL4 in lymph
node metastasis may be due to its role in epigenetic
modulation of Bmi-1, leading to repression of the involved
genes in epithelial cell differentiation. Such sustained re-
pression may cause EMT in CRC cells leading to the loss of
cell adhesion and subsequent release of tumoral cells from
the epithelium into the local lymph nodes. This may be an
oncogenic role of SALL4 in cell fate decision in CRC
through Bmi-1 activation. In support of this hypothesis,
previous analysis of the SALL4/Bmi-1 regulatory pathway
in cancer stem cells revealed the potential of this pathway
as an attractive target for therapeutic intervention [34].
SALL4 is an important regulator not only of the stem-
ness state and survival of several types of normal stem
cells, but also the survival and expansion of cancer cells
and possibly cancer stem cells [12]. SALL4 not only
binds genes involved in important cell growth pathways
such as Wnt, apoptosis, PTEN, and NF-kappaB signal-
ing, but gene expression levels in these pathways are also
affected by reduction of SALL4.
SALL4 regulates cell survival by targeting a wide range
of genes in both pro- and anti-apoptotic pathways [35].
Furthermore, expression of such genes is regulated by
SALL4 in ES cells [12]. In CRC samples, overexpression
of SALL4 may have a fundamental role in tumor cell
survival by transcriptional repression of pro-apoptotic
genes such as PTEN. Interestingly, PTEN expression is
decreased or absent within colorectal tumor cells com-
pared to related normal tissues [36]. The lack of PTEN
expression in CRC samples was encountered as a result
of various mutations in the PTEN gene [36]. Based on
our results, we also hypothesize a probable role for
SALL4 overexpression in repression of PTEN transcrip-
tion, which leads to down-regulation of PTEN in CRC
cells. This hypothesis is supported by the following: first,
down-regulation of SALL4 results in apoptosis [34],
which may partly being due to activation of pro-
apoptotic genes such as PTEN. It has been reported that
SALL4 functions as a regulator of cell survival in human
acute promyelocytic leukemia cells by targeting and
regulating a wide range of genes in both pro-apoptotic
and anti-apoptotic pathways [34]. Second, it has been
established that PTEN has tumor-suppressive effects in
CRC cells [37]. Therefore, SALL4 overexpression may
regulate CRC cells survival by inhibiting apoptosis via
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suppressor gene PTEN.
Conclusion
This study elucidates the clinical importance of stem cell
marker SALL4 expression at the mRNA level for the
first time in CRC. We have shown SALL4 may be a new
molecular marker of metastatic tumor. Its probable role
in CRC progression is confirmed by its overexpression
in CRC and its correlation to lymph node metastasis, a
determinant of poor prognosis. Overexpression of
SALL4 mRNA in colorectal cancer may have a role in
the progression of the disease and may shed a light in
the elucidation of pathophsiology of colorectal cancer.
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